Best Cell & Gene Therapy CDMOs in Asia
Cell & Gene Therapy manufacturers on CDMO Signal: 24 listed with manufacturing sites in Asia, 23 with a Signal Score. Together they have 30 FDA inspections on file (including 16 NAI, 11 VAI and 3 OAI), 6 FDA warning letters and 44 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
Cell & Gene Therapy CDMOs in Asia with the most regulatory evidence on file
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 16 NAI (no action), 11 VAI (voluntary action), 3 OAI (official action). Leading inspection & GMP sites: Denmark (23), India (13), United States (12), Germany (6), INDIA (5).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 2 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 3 |
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.1 | 99.2 | 3 insp · 4 GMP | 2025-11-25 · NAI | Limited | — |
| 4 |
WB2
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | 2026-07-03 · VAI | — | — |
| 5 |
LB
|
81.6 | 100.0 | 2 insp · 0 GMP | 2026-09-18 · NAI | — | — |
| 6 |
SG
|
80.3 | 100.0 | 3 insp · 0 GMP | 2025-02-20 · NAI | — | — |
| 7 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 8 |
GZ
|
78.1 | 100.0 | 1 insp · 0 GMP | 2025-08-27 · NAI | Available | — |
| 9 |
BC
|
75.7 | 93.1 | 7 insp · 2 GMP | 2025-09-03 · VAI | — | — |
| 10 |
PBI
Pennington, NJ · Nanjing, CN
|
64.0 | — | — | None on file | — | — |
| 11 |
HG
|
63.0 | — | — | None on file | — | — |
| 12 |
SM
|
63.0 | — | — | None on file | — | — |
| 13 |
EA
Singapore, Singapore
|
63.0 | — | — | None on file | — | — |
| 14 |
IP
Ahmedabad, India
|
62.3 | 68.9 | 3 insp · 5 GMP | 2025-09-16 · OAI Warning letter 2026-03-30 |
— | — |
| 15 |
HX
|
59.0 | — | — | None on file | — | — |
| 16 |
CTP
Melbourne, Australia
|
59.0 | — | — | None on file | — | — |
| 17 |
SS
Bloomington, IN
|
59.0 | — | — | None on file | — | — |
| 18 |
TR
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | None on file | — | 8 programs |
| 19 |
UB
|
56.5 | — | — | None on file | — | — |
| 20 |
GC
Yongin, KR
|
56.5 | — | — | None on file | — | — |
| 21 |
CH
Seongnam, KR
|
56.5 | — | — | None on file | — | — |
| — |
Chongqing, China
|
Profiled | — | 1 insp · 0 GMP | 2024-03-29 · NAI | — | — |